Zhinuan Yu, Ph.D.

Mar 31, 2021View PDF

Dr. Yu has over 20 years of experience in the pharmaceutical industry and led the statistical support at Celgene for multiple high-priority programs, including thalidomide, lenalidomide, pomalidomide and bb2121 (CAR-T).